Company profile for ENA Respiratory

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ENA Respiratory is a biotechnology company aiming to transform the treatment and prevention of respiratory infections in at-risk populations. Ena Respiratory is developing novel, synthetic innate immunomodulators for the prevention of respiratory viral and bacterial infections. The company is based in Melbourne, Australia and it has secured a Series A investment from the Brandon Capital managed Medical Research Commercialisat...
ENA Respiratory is a biotechnology company aiming to transform the treatment and prevention of respiratory infections in at-risk populations. Ena Respiratory is developing novel, synthetic innate immunomodulators for the prevention of respiratory viral and bacterial infections. The company is based in Melbourne, Australia and it has secured a Series A investment from the Brandon Capital managed Medical Research Commercialisation Fund (MRCF) and Uniseed.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Australia
Address
Address
31 Queen Street, Melbourne 3000
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/22/3170783/0/en/ENA-Respiratory-Attracts-US-22-4m-AU-34m-to-Fund-Phase-II-Development-of-INNA-051-Nasal-Spray-Designed-to-Protect-Against-Symptomatic-Viral-Respiratory-Infections.html

GLOBENEWSWIRE
22 Oct 2025

https://www.globenewswire.com/news-release/2025/05/06/3074736/0/en/ENA-Respiratory-Appoints-International-Pharma-Experts-as-Strategic-Advisors-to-Support-Development-of-INNA-051-Antiviral-Host-Defence-Enhancer.html

GLOBENEWSWIRE
06 May 2025

https://www.globenewswire.com/news-release/2025/04/09/3058150/0/en/ENA-Respiratory-Partners-with-University-of-Maryland-and-Leading-Respiratory-Disease-Expert-to-Conduct-Phase-2-Study-of-INNA-051-Antiviral-Host-Defence-Enhancer.html

GLOBENEWSWIRE
09 Apr 2025

https://www.globenewswire.com/news-release/2025/04/02/3053983/0/en/ENA-Respiratory-Announces-Publication-Supporting-the-Potential-of-its-Novel-Intranasal-Therapy-INNA-051-to-Reduce-the-Impact-of-Viral-Respiratory-Infections-in-Older-Adults.html

GLOBENEWSWIRE
02 Apr 2025

https://www.globenewswire.com/news-release/2025/02/10/3023216/0/en/ENA-Respiratory-Receives-US-5m-Investment-from-Flu-Lab-to-Support-Clinical-Development-of-Novel-Intranasal-Antiviral-Host-Defence-Immune-Enhancer-INNA-051.html

GLOBENEWSWIRE
10 Feb 2025

https://www.globenewswire.com/news-release/2025/01/28/3016114/0/en/ENA-Respiratory-Publishes-Review-of-Development-of-Novel-Intranasal-Antiviral-Host-Defense-Immune-Enhancer-INNA-051-in-Antiviral-Research.html

GLOBENEWSWIRE
28 Jan 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty